THERAPEUTIC AGENT FOR T CELL TUMOR

WIPO Patent Application WO/2024/085182

A1

The present invention addresses the problem of providing a novel method for treating T cell tumor, whereby it becomes possible to induce the cell damage of a tumor cell and which is less likely to cause immunodeficiency.　According to the present invention, a T cell tumor therapeutic agent comprising a bispecific antigen-binding molecule is provided, in which the bispecific antigen-binding molecule includes (1) at least one segment capable of binding specifically to a target tumor antigen expressed in a T cell tumor cell and (2) at least one segment capable of binding specifically to a normal T cell-side target antigen having a subtype. The target tumor antigen expressed in a T cell tumor cell is not present in a normal T cell. If the target tumor antigen is present in a normal T cell, when the bispecific antigen-binding molecule is bound to an antigen that is the same as the target tumor antigen and is present in a normal T cell, the normal T cell is not substantially activated. When the bispecific antigen-binding molecule is bound to a normal T cell-side target antigen, the normal T cell is activated and the subtype of the normal T cell-side target antigen is present at a ratio that is sufficient for providing a sufficient number of activated T cell for the treatment of T cell tumor.

ISHIDA YOJI (JP)
FUKUSHIMA TAKAYOSHI (JP)
CHIKADA TSUBASA (JP)
ASANO HIKARI (JP)
TSUCHIYA TOSHIYUKI (JP)

PCT/JP2023/037683

April 25, 2024

October 18, 2023

Click for automatic bibliography generation  

MEIJI SEIKA PHARMA CO LTD (JP)

A61K39/395; A61P35/00; A61P35/02; A61P43/00; C07K16/28; C07K16/30; C12N15/13

WO2021217085A1	2021-10-28
WO2021173896A1	2021-09-02

JP2022512849A	2022-02-07
JP2020527027A	2020-09-03

SIKS & CO. (JP)

View/Download PDF      PDF Help

Previous Patent: RESIST COMPOSITION, RESIST PATTERN FORMATION METHOD, AND COMPOUND

Next Patent: ADHESIVE AGENT, ADHESIVE SHEET, MULTILAYER BODY, AND DISPLAY